Comparative Pharmacology
Head-to-head clinical analysis: NUCYNTA ER versus STADOL PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUCYNTA ER versus STADOL PRESERVATIVE FREE.
NUCYNTA ER vs STADOL PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tapentadol is a mu-opioid receptor agonist and norepinephrine reuptake inhibitor, providing analgesic effects through opioid receptor activation and modulation of descending pain pathways.
Butorphanol is a synthetic agonist-antagonist opioid analgesic that exerts its effects primarily through binding to kappa-opioid receptors and, to a lesser extent, mu-opioid receptors, producing analgesia and sedation. It also has partial antagonist activity at mu receptors.
100 mg orally every 12 hours, titrated from 50 mg every 12 hours; maximum 200 mg every 12 hours.
0.5–2 mg intravenously or intramuscularly every 3–4 hours as needed for pain. Alternatively, 1–2 mg as a single dose, may repeat in 30–60 minutes if needed.
None Documented
None Documented
Terminal elimination half-life: 4.1 hours (range 3.3–4.7 h) after single oral dose; steady state: 4.4 h. No clinically relevant accumulation.
Terminal elimination half-life is 2.5–3.3 hours in adults; prolonged to 4–6 hours in elderly or hepatic impairment.
Renal: 99% (tapentadol and glucuronide conjugates); Fecal: <1%; unchanged tapentadol: <5%.
Primarily hepatic metabolism (glucuronidation) to inactive metabolites; renal excretion accounts for <5% unchanged drug. Approximately 70% of dose excreted in urine as metabolites, 20% in feces.
Category C
Category C
Opioid Analgesic
Opioid Analgesic